Regarding Professor RAPOPORT - Mt Sinai New York
1. Joel had a MOU - Agreement between IHL and RespireRX (USA)
Mate this is the ASX release 15th February, 2019
https://stocknessmonster.com/announcements/ihl.asx-3A510710/
2 .This arrangement between RespireRx and IHL "may have" occurred when Professor Rapoport was a member
of the RespireRX Clinical Research Advisory Board
https://www.bloomberg.com/press-releases/2017-11-30/respirerx-pharmaceuticals-inc-announces-publication-of-phase-2b-pace-study-once-per-night-treatment-with-dronabinol-provides3. This could suggest Joel has had a previous working relationship with Professor Rapoport, or at the very least Joel would have known of Professor RAPOPORT and his Sleep Medicine work since 2019 through the dealings with RESPIRE RX.
4. What does all of this mean?
Well Joel had a working relationship with Dr George from an agreement back in September 2018
https://stocknessmonster.com/announcements/ihl.asx-3A501312/
Dr George is now an IHL Director and major shareholder via the APIRx Acquisition.
5. So if a past relationship existed between Joel and Professor RAPOPORT and that relationship is still ongoing then.......
MAYBE..... Professor RAPOPORT could
potentially become our Cheif Advisor / Investigator for our USA IHL-42X Sleep Apnoea Trials.
6. Why would Professor RAPOPORT be a good fit for IHL-42x Trials?
A. His relationship with a Prestigious Institution - Mt Sinai - New York
B. His Sleep Medicine Experience
Biography
David M. Rapoport, MD, is currently Professor of Medicine in the Division of Pulmonary, Critical Care and Sleep Medicine, and Research Director of the Mount Sinai Health System Integrative Sleep Center.
Dr. Rapoport received an SB in Physics at MIT and an MD at the Albert Einstein College of Medicine. He did internship and residency training in Internal Medicine at Roosevelt Hospital and Pulmonary training at Bellevue Hospital and New York University. He was on the faculty at NYU from 1980 to 2015 and established and directed the Sleep Medicine Program at NYU. In 2016 he joined the faculty of the Icahn School of Medicine at Mt. Sinai.
Dr. Rapoport’s research interests center around pulmonary and sleep physiology. He has spent his career studying control of breathing and of the upper airway, the epidemiology, causes, consequences and treatments of sleep disordered breathing. He is a “gadgeteer” by nature and has been involved since its origin in the development of nasal CPAP, the main treatment modality for obstructive sleep apnea. He is responsible for modifications of CPAP delivery aimed at making it more accessible and improving quality of the treatment and comfort/compliance with its use.
Dr. Rapoport was the New York Cohort Principle Investigator of the Sleep Heart Health Study, a large multicenter NIH sponsored epidemiologic study that assessed the cardiovascular consequences of sleep disordered breathing and of the CATNAP study, which aimed to evaluate the benefits of CPAP in mild to moderate obstructive sleep apnea. He is part of PRIDE, an NIH sponsored program that helps train and mentor minority junior faculty in preparation for careers in academic research. He is Principle Investigator or co-Principle Investigator of several industry-sponsored studies involving sleep disordered breathing and other sleep disorders.He is the founder and president of the Foundation for Research in Sleep Disorders, a non-profit that supports research and training in sleep medicine.
Dr. Rapoport originated and was the director of the NYU Sleep Medicine Fellowship Training Program until 2010; he has trained many clinical and research fellows in Sleep Medicine. He is a member of the American Thoracic Society, the American Physiological Society, the American Academy of Sleep Medicine and the Sleep Research Society.He is peer reviewer for multiple medical journals.
Dr. Rapoport is (co-)author of over 110 publications in peer-reviewed, international journals.
https://orcid.org/0000-0002-4855-2600
7. Clearly, he has the credentials!
GLAH .... How are we going Joel? 
